Business Wire

CA-LIVERAMP

28.2.2024 17:01:28 CET | Business Wire | Press release

Share
LiveRamp Launches Unified Data Collaboration Platform Featuring Composable Technology

LiveRamp (NYSE: RAMP) today unveiled the next generation of the /LiveRamp Data Collaboration Platform, which brings together solutions for the end-to-end marketing lifecycle onto a single platform. The unified offering introduces new capabilities such as a simplified user interface, composable technology for cross-cloud interoperability, and a partner marketplace where innovative third-party developers can build applications showcasing their trusted expertise. Built on a foundation of durable, authenticated technology designed to withstand signal loss, the /LiveRamp Data Collaboration Platform offers functionality to proactively address evolving privacy considerations while accelerating forward-looking data collaboration use cases.

Gartner® findings show “Marketing has an outsized role in data and analytic activities across the enterprise, with 71% of marketing data and analytics teams responsible for owning at least one element of data strategy for their organization.” By bringing all of its capabilities into a single user interface with simplified orchestration, LiveRamp enables customers to more easily connect audiences across partners. Supporting modern data architectures with a focus on decentralized data reduces cloud complexity, improving cloud usability for all business users while resolving IT infrastructure constraints. Customer advantages include greater ease-of-use and streamlined functionality that unlock greater value across all of their data collaboration needs.

  • Increase simplicity using a single user interface built on a foundation of best-in-class identity, global authenticated connectivity, and proprietary privacy-enhancing technologies
  • Enhance the user experience and accelerate speed-to-value with new ingestion pipelines that reduce turnaround time from days to hours. Self-service tools allow the permissioning of datasets and segments, and a new notification system—capable of integrating with workplace tools including Slack—enables users to control how they receive information
  • Reach audiences ecosystem-wide using an enhanced activation and segmentation experience centered on users, campaigns and cross-audience segmentation. Further improve marketing performance by integrating with technologies such as Google PAIR designed to combat the loss of third-party cookies and other deprecating signals.
  • Unlock new partnerships across second and third-party data with the flexibility to collaborate wherever your first-party data lives, across the widest range of use cases, from one location
  • Leverage a new, partner application marketplace starting with integrated discovery, access, and deployment of measurement solutions from LiveRamp’s global network of partners

“A core tenet of the Albertsons Media Collective is to foster a more interconnected, collaborative ecosystem that increases access to data while minimizing data movement,” said Evan Hovorka, VP of Product and Innovation, Albertsons Media Collective. “LiveRamp has helped us advance this pledge with future-ready solutions that grow signal fidelity, enhance privacy, and scale data collaboration across the channels that matter most to our network. LiveRamp bringing these capabilities together more seamlessly will not only accelerate our own partnership, but the downstream value we deliver to our customers, advertisers, and ecosystem at large.”

“Circana’s Lift solution, a gold standard in retail and CPG measurement, incorporates household level data to unlock critical insights for advertisers, enabling them to measure and optimize media investments to improve sales performance,” said Harvey Goldhersz, EVP of Product at Circana. “Through LiveRamp, advertisers can now pinpoint which creative messages, ad formats, audience segments, and media placements drive retail sales most effectively and efficiently. Advertisers who use Circana’s Lift solution improve return on advertising spend (ROAS) up to 80%. We’re thrilled to switch on this capability for LiveRamp, bringing Circana’s speed, superior coverage, and accuracy to an even wider audience.”

The launch of the unified /LiveRamp Data Collaboration Platform follows the company’s acquisition of Habu to accelerate data collaboration through enhanced clean room technology. Customers using the LiveRamp Clean Room, powered by Habu on its platform can measure campaigns across all walled gardens, media platforms and programmatic channels while connecting data seamlessly across clouds, warehouses and clean rooms.

“LiveRamp’s customers have been asking for solutions with greater simplicity and scale to unlock the value of data and drive a competitive advantage,” added Kimberly Bloomston, Chief Product Officer at LiveRamp. “The launch of our fully unified platform delivers on this need by setting a new standard for powerful data collaboration built on privacy-enhancing technologies that withstand evolving signal loss and privacy requirements. LiveRamp’s recent acquisition of Habu further strengthens our ability to help customers collaborate with anyone, activate data anywhere, and measure everywhere it matters.”

Learn more about the wide range of data collaboration use cases LiveRamp can unlock for your company at liveramp.com/our-platform.

About LiveRamp

LiveRamp is the data collaboration platform of choice for the world’s most innovative companies. A groundbreaking leader in consumer privacy, data ethics, and enterprise identity, LiveRamp is setting the new standard for building a connected customer view with unmatched clarity and context while protecting precious brand and consumer trust. LiveRamp offers complete flexibility to collaborate wherever data lives to support the widest range of data collaboration use cases—within organizations, between brands, and across its premier global network of top-quality partners.

Hundreds of global innovators, from iconic consumer brands and tech giants to banks, retailers, and healthcare leaders turn to LiveRamp to build enduring brand and business value by deepening customer engagement and loyalty, activating new partnerships, and maximizing the value of their first-party data while staying on the forefront of rapidly evolving compliance and privacy requirements. LiveRamp is based in San Francisco, California with offices worldwide. Learn more at www.liveramp.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240228206793/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release

If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release

This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release

New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye